Crosstalk between miRNAs and signaling pathways involved in pancreatic cancer and pancreatic ductal adenocarcinoma.


Journal

European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354

Informations de publication

Date de publication:
15 Jun 2021
Historique:
received: 19 08 2020
revised: 19 01 2021
accepted: 02 03 2021
pubmed: 13 3 2021
medline: 19 5 2021
entrez: 12 3 2021
Statut: ppublish

Résumé

Pancreatic cancer (PC) is the seventh leading cause of cancer-related deaths worldwide with 5-year survival rates below 8%. Most patients with PC and pancreatic ductal adenocarcinoma (PDAC) die after relapse and cancer progression as well as resistance to treatment. Pancreatic tumors contain a high desmoplastic stroma that forms a rigid mass and has a potential role in tumor growth and metastasis. PC initiates from intraepithelial neoplasia lesions leading to invasive cancer through various pathways. These lesions harbor particular changes in signaling pathways involved in the tumorigenesis process. These events affect both the epithelial cells, including the tumor and the surrounding stroma, and eventually lead to the formation of complex signaling networks. Genetic studies of PC have revealed common molecular features such as the presence of mutations in KRAS gene in more than 90% of patients, as well as the inactivation or deletion mutations of some tumor suppressor genes including TP53, CDKN2A, and SMAD4. In recent years, studies have also identified different roles of microRNAs in PC pathogenesis as well as their importance in PC diagnosis and treatment, and their involvement in various signaling pathways. In this study, we discussed the most common pathways involved in PC and PDAC as well as their role in tumorigenesis and progression. Furthermore, the miRNAs participating in the regulation of these signaling pathways in PC progression are summarized in this study. Therefore, understanding more about pathways involved in PC can help with the development of new and effective therapies in the future.

Identifiants

pubmed: 33711308
pii: S0014-2999(21)00159-X
doi: 10.1016/j.ejphar.2021.174006
pii:
doi:

Substances chimiques

MicroRNAs 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

174006

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Ziba Lotfi (Z)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Shiva Najjary (S)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Fariba Lotfi (F)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Mohammad Amini (M)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Amir Baghbanzadeh (A)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Darya Javad Rashid (DJ)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Elmira Roshani Asl (ER)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.

Behzad Baradaran (B)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: baradaranb@tbzmed.ac.ir.

Ahad Mokhtarzadeh (A)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: mokhtarzadehah@tbzmed.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH